公开(公告)号：WO2022026336A1

公开(公告)日：2022-02-03

申请号：PCT/US2021/043062

申请日：2021-07-23

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： GELFMAN, Sahar ,  LIGOCKI, Ann ,  COPPOLA, Giovanni ,  BARIS, Aris ,  MOSCATI, Arden ,  STAHL, Eli A. ,  KOSMICKI, Jack A. ,  FERREIRA, Manuel Allen Revez ,  ROMANO, Carmelo

IPC: C07K16/40 ,  A61K31/7088 ,  C12N9/48 ,  A61P37/02 ,  A61P27/00 ,  A61P17/00 ,  A61P19/00 ,  A61K31/713 ,  A61P25/00 ,  C07K14/8103 ,  C12N9/485 ,  C12Y304/11

Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and/or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.

公开(公告)号：WO2023064850A1

公开(公告)日：2023-04-20

申请号：PCT/US2022/078037

申请日：2022-10-13

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： GELFMAN, Sahar ,  LIGOCKI, Ann ,  COPPOLA, Giovanni ,  BARAS, Aris ,  MOSCATI, Arden ,  STAHL, Eli A. ,  ROMANO, Carmelo ,  MENDEZ HUERGO, Santiago ,  WEYNE, Jonathan ,  VAN ZYL, Tave

IPC: C12N15/113 ,  A61K31/7088 ,  A61P27/02

Abstract: The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.

公开(公告)号：WO2022216832A1

公开(公告)日：2022-10-13

申请号：PCT/US2022/023685

申请日：2022-04-06

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： GELFMAN, Sahar ,  LIGOCKI, Ann ,  COPPOLA, Giovanni ,  BARAS, Aris ,  MOSCATI, Arden ,  STAHL, Eli A. ,  KOSMICKI, Jack A. ,  FERREIRA, Manuel Allen Revez ,  ROMANO, Carmelo

IPC: C07K16/40 ,  A61K31/7088 ,  C12N9/48 ,  A61P37/02 ,  A61P27/00 ,  A61P17/00 ,  A61P19/00 ,  A61K31/713 ,  A61K39/3955 ,  C07K16/2833 ,  C12N9/485 ,  C12Q1/00 ,  C12Q1/6881

Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.